You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Details for Patent: 10,076,614


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,076,614
Title:Nasal delivery devices
Abstract: A nasal delivery device for delivering substance to a nasal cavity of a subject comprises: a housing (15); a nosepiece (17) for fitting to a nasal cavity of the subject; a mouthpiece (19) through which the subject in use exhales; and a flexible coupling (20) which couples the mouthpiece to the housing, wherein the flexible coupling provides for asymmetric translation of the mouthpiece relative to the nosepiece.
Inventor(s): Djupesland; Per Gisle (Oslo, NO), Gordon; Joseph (Mansfield, MA), Leclerc; Michael (Cranston, RI), Mahmoud; Ramy A (Skillman, NJ), Siwinski; Shane (Providence, RI)
Assignee: OptiNose AS (Oslo, NO)
Application Number:14/380,801
Patent Claim Types:
see list of patent claims
Delivery; Device;
Patent landscape, scope, and claims:

United States Patent 10,076,614: A Comprehensive Analysis of Scope and Claims

Introduction

The United States Patent 10,076,614, titled "Nasal delivery devices," is a significant innovation in the field of medical devices, particularly for the delivery of substances to the nasal cavity. This patent, granted to the inventors, outlines a novel design and method for delivering medicaments, vaccines, or other substances directly to the nasal airway. Here, we delve into the details of the patent, its scope, and the broader patent landscape it inhabits.

Background and Context

The nasal airway is a complex anatomical structure that includes two nasal cavities separated by the nasal septum. It communicates with the nasopharynx, oral cavity, and lower airway, making it a critical pathway for respiratory and systemic drug delivery[1].

Patent Overview

Invention Description

The patent describes a nasal delivery device designed to deliver substances such as liquids, suspensions, solutions, or powders containing medicaments or vaccines to the nasal airway. The device consists of a housing, a nosepiece, and various components to ensure efficient delivery.

Key Components

  • Housing: The main body of the device that contains the substance to be delivered.
  • Nosepiece: Designed to fit into the nasal cavity, ensuring proper placement and delivery of the substance.
  • Coupling Member: Connects the housing to the nosepiece, facilitating the transfer of the substance.
  • Longitudinal Axis: The alignment of the device to match the anatomy of the nasal cavity[1].

Scope of the Patent

Claims

The patent includes several claims that define the scope of the invention. These claims are categorized into independent and dependent claims.

  • Independent Claims: These define the broadest scope of the invention, including the overall structure and function of the nasal delivery device.
  • Dependent Claims: These narrow down the scope by specifying particular features or embodiments of the device, such as the material of the nosepiece or the mechanism of substance delivery[1].

Claim Types

  • Mechanically Breath-Triggered Claims: The device is activated by the user's breath, ensuring synchronized delivery with inhalation.
  • Exhalation-Activated Claims: The device can also be activated by exhalation, providing an alternative delivery mechanism[1].

Technical Details

Delivery Mechanism

The device is designed to deliver substances in various forms, including liquids and powders. The nosepiece is crucial for ensuring that the substance reaches the intended area within the nasal cavity.

Materials and Construction

The device may be made from materials that provide elastic properties, facilitating deformation without breaking. This ensures comfort and safety during use[1].

Patent Classification

The patent is classified under several categories within the International Patent Classification (IPC) system:

  • A61M15/00: Inhalators
  • A61M15/0091: Mechanically breath-triggered inhalators
  • A61M15/0098: Inhalators activated by exhalation
  • A61M2202/06: Solids, including powders[1].

Market and Industrial Impact

Competitive Landscape

The issuance of this patent strengthens the intellectual property portfolio of companies involved in nasal drug delivery. For example, Optinose, a company specializing in nasal spray technologies, has also secured multiple patents for their products, such as XHANCE (fluticasone propionate)[4].

Innovation and Advancements

This patent contributes to the advancement of nasal drug delivery technologies, offering improved efficacy and patient compliance. The innovative design and functionality of the device make it a valuable asset in the pharmaceutical and medical device industries.

Legal and Regulatory Considerations

Inventorship

The determination of true and only inventors is crucial for the validity of the patent. US patent law requires that the inventors listed are those who conceived the idea and reduced it to practice[2].

Patent Enforcement and Challenges

A thorough job of invention disclosure is essential to ensure that the patent remains enforceable. Incorrect or incomplete identification of inventors can lead to challenges and potential invalidation of the patent[2].

Future Directions and Trends

Small Claims Patent Court

There is an ongoing discussion about the establishment of a small claims patent court to address issues related to patent disputes, particularly for smaller entities. This could impact the enforcement and litigation landscape for patents like US 10,076,614[5].

Patent Scope Measurements

The USPTO has developed datasets and measures to analyze patent scope, which can help in understanding the breadth and depth of patent protection. This is particularly relevant for assessing the competitive position of patented technologies[3].

Key Takeaways

  • Innovative Design: The patent introduces a novel nasal delivery device with a housing, nosepiece, and coupling member.
  • Delivery Mechanisms: The device can be mechanically breath-triggered or activated by exhalation.
  • Materials: The use of elastic materials ensures comfort and safety.
  • Market Impact: Strengthens the intellectual property portfolio in the pharmaceutical and medical device industries.
  • Legal Considerations: Proper inventorship and thorough invention disclosure are critical for patent validity.

FAQs

Q: What is the primary purpose of the nasal delivery device described in US Patent 10,076,614?

A: The primary purpose is to deliver substances such as medicaments, vaccines, or other pharmaceuticals directly to the nasal airway.

Q: How is the device activated?

A: The device can be activated either mechanically by the user's breath or by exhalation.

Q: What materials are recommended for the construction of the device?

A: Materials providing elastic properties are recommended to facilitate deformation without breaking.

Q: Under which IPC categories is the patent classified?

A: The patent is classified under A61M15/00, A61M15/0091, A61M15/0098, and A61M2202/06.

Q: Why is proper inventorship important for this patent?

A: Proper inventorship is crucial to ensure the patent's validity and enforceability, as incorrect identification can lead to challenges and potential invalidation.

Sources

  1. US10076614B2 - Nasal delivery devices - Google Patents
  2. Determining Inventorship for US Patent Applications
  3. Patent Claims Research Dataset - USPTO
  4. Optinose Announces Issuance of Four Additional U.S. Patents Covering XHANCE
  5. U.S. Patent Small Claims Court - ACUS

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,076,614

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 1 to 2 of 2 entries

Foreign Priority and PCT Information for Patent: 10,076,614

PCT Information
PCT FiledFebruary 25, 2013PCT Application Number:PCT/EP2013/053747
PCT Publication Date:August 29, 2013PCT Publication Number: WO2013/124492

International Family Members for US Patent 10,076,614

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Australia 2013223973 ⤷  Subscribe
Canada 2865353 ⤷  Subscribe
China 104428026 ⤷  Subscribe
Denmark 2817054 ⤷  Subscribe
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 4 of 4 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.